Brooke was only three years old when she first learned about desmoid tumors. “My mother had six or seven,” she recalls. Brooke’s mother also had 28 surgeries related to her desmoid tumors and multiple ...

Panelists discuss the questions below in this video. What is the epidemiology and prognosis of desmoid tumor? Where on the body are desmoid tumors usually found? Can you please describe the ...

Varegacestat reduced the risk of disease progression or death by 84% compared with placebo in patients with progressing desmoid tumors. Topline data were announced from a phase 3 trial evaluating ...

Panelists discuss the questions below in this video. What is the pathophysiology of desmoid tumors and how does this differ from other soft tissue cancers?What is in your differential diagnosis when ...

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the U.S. Food and Drug ...

(RTTNews) - Immunome, Inc. (IMNM) is scheduled to report topline Phase 3 results of its lead drug candidate, Varegacestat, in desmoid tumors, dubbed RINGSIDE trial, today. Desmoid tumors are rare, ...

In a continuation of its awareness and education efforts around desmoid tumors, SpringWorks Therapeutics has partnered with celebrity jewelry designer and patient advocate Jennifer Fisher. Just over ...

The US Food and Drug Administration approved nirogacestat (Ogsiveo, SpringWorks Therapeutics, Inc) to treat progressive, unresectable, recurrent, or refractory desmoid tumors in adults. Nirogacestat, ...

(RTTNews) - Immunome, Inc. (IMNM) Monday reported positive data from its pivotal Phase-3 RINGSIDE trial, in patients with desmoid tumors, with Varegacestat improving progression-free survival and ...

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial In the phase III ...

The U.S. Food and Drug Administration has approved SpringWorks Therapeutics Inc.'s Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment.